Objectives: In chronic myeloid leukemia, after promising results in major cytogenetic remission (MCR), longterm survival data on imatinib treatment is of particular interest, especially in relation to former standard treatment based on interferon-alpha...
Keywords: Prognosis, cumulative survival rate, myeloid leukemia, chronic, imatinib mesylate
01/2005 | Methods of Information in Medicine, Schattauer